{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:57:52Z","timestamp":1792094272365,"version":"4.4.0"},"reference-count":281,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and\/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient\u2019s inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.<\/jats:p>","DOI":"10.3389\/fphys.2021.746494","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:08:05Z","timestamp":1634144885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":151,"title":["Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets"],"prefix":"10.3389","volume":"12","author":[{"given":"Marta","family":"Reina-Couto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Pereira-Terra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janete","family":"Quelhas-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Silva-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Albino-Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease.","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].","volume":"111","author":"Abbate","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure.","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jacbts.2016.09.004","article-title":"Myeloperoxidase inhibition improves ventricular function and remodeling after experimental myocardial infarction.","volume":"1","author":"Ali","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/cvr\/cvy166","article-title":"Conflicting vascular and metabolic impact of the IL-33\/sST2 axis.","volume":"114","author":"Altara","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan.","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cvr\/cvp241","article-title":"Interleukin 8 and cardiovascular disease.","volume":"84","author":"Apostolakis","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs Placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial.","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.20021426","article-title":"Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.","volume":"197","author":"Askari","year":"2003","journal-title":"J. Exp. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00129784-200707020-00004","article-title":"Potential mechanisms of benefit with thalidomide in chronic heart failure.","volume":"7","author":"Aukrust","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2165\/00129784-200707050-00003","article-title":"The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here?","volume":"7","author":"Bailey","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/ehf2.12681","article-title":"Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature.","volume":"7","author":"Bajaj","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10741-018-9716-x","article-title":"Role of cytokines and inflammation in heart function during health and disease.","volume":"23","author":"Bartekova","year":"2018","journal-title":"Heart Fail Rev"},{"key":"B16","first-page":"439","article-title":"High-sensitivity C-reactive protein: clinical importance.","volume":"29","author":"Bassuk","year":"2004","journal-title":"Curr. Probl. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.healun.2004.06.021","article-title":"Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling.","volume":"23","author":"Berry","year":"2004","journal-title":"J. Heart Lung Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026475","article-title":"Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis.","volume":"100","author":"Bian","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jchf.2019.03.008","article-title":"Predicting risk for incident heart failure with omega-3 fatty acids: From MESA.","volume":"7","author":"Block","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cardfail.2008.06.415","article-title":"Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.","volume":"14","author":"Boisot","year":"2008","journal-title":"J. Card Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction.","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: The INDIE-HFpEF randomized clinical trial.","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1002\/ehf2.12882","article-title":"Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study.","volume":"7","author":"Borovac","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/01.cir.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure.","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail."},{"key":"B28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000512772","article-title":"Colchicine for left ventricular infarct size reduction in acute myocardial infarction: A Phase II, multicenter, randomized, double-blinded, placebo-controlled study protocol - The COVERT-MI study.","volume":"146","author":"Bresson","year":"2021","journal-title":"Cardiology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/FJC.0000000000000591","article-title":"Effect of interleukin-1 blockade on left ventricular systolic performance and work: A post hoc pooled analysis of 2 clinical trials.","volume":"72","author":"Buckley","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1161\/01.CIR.0000096055.62724.C5","article-title":"Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells.","volume":"108","author":"Calabro","year":"2003","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00281-019-00767-y","article-title":"The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification.","volume":"41","author":"Carracedo","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01382-2","article-title":"What is the role of the inflammation in the pathogenesis of heart failure?","volume":"22","author":"Castillo","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure.","volume":"8","author":"Cavalli","year":"2017","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/1755-5922.12076","article-title":"Pentoxifylline in heart failure: a meta-analysis of clinical trials.","volume":"32","author":"Champion","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.CCM.0000297160.48694.90","article-title":"Cytokines and acute heart failure.","volume":"36","author":"Chen","year":"2008","journal-title":"Crit. Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1073\/pnas.1424236112","article-title":"Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33.","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018549","article-title":"Interleukin 6 and development of heart failure with preserved ejection fraction in the general population.","volume":"10","author":"Chia","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology.","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"B39","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1096\/fj.201801017R","article-title":"Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes.","volume":"33","author":"Chiurchiu","year":"2019","journal-title":"FASEB J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","article-title":"Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production.","volume":"114","author":"Choi","year":"2009","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/med.21599","article-title":"Inducible nitric oxide synthase: Regulation, structure, and inhibition.","volume":"40","author":"Cinelli","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2019.09.006","article-title":"Myeloperoxidase and the risk of CKD progression, cardiovascular disease, and death in the Chronic Renal Insufficiency Cohort (CRIC) Study.","volume":"76","author":"Correa","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.repc.2015.09.006","article-title":"Statins and oxidative stress in chronic heart failure.","volume":"35","author":"Costa","year":"2016","journal-title":"Rev. Port Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2006.02.038","article-title":"The pathophysiology of acute heart failure\u2013is it all about fluid accumulation?","volume":"155","author":"Cotter","year":"2008","journal-title":"Am. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1161\/01.cir.101.12.1358","article-title":"L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock.","volume":"101","author":"Cotter","year":"2000","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/s0195-668x(03)00193-3","article-title":"LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study.","volume":"24","author":"Cotter","year":"2003","journal-title":"Eur. Heart J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/heart.88.6.564","article-title":"Nitric oxide and myocardial function in heart failure: friend or foe?","volume":"88","author":"Cotton","year":"2002","journal-title":"Heart"},{"key":"B49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/apha.12488","article-title":"Myeloperoxidase evokes substantial vasomotor responses in isolated skeletal muscle arterioles of the rat.","volume":"214","author":"Csato","year":"2015","journal-title":"Acta Physiol. (Oxf)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64702-0","article-title":"Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases.","volume":"10","author":"Cuinet","year":"2020","journal-title":"Sci. Rep."},{"key":"B51","author":"Dallos","year":"2020","journal-title":"National Library of Medicine (U.S.). Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. Identifier NCT04347226"},{"key":"B52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0008-6363(99)00262-x","article-title":"CXC-chemokines, a new group of cytokines in congestive heart failure\u2013possible role of platelets and monocytes.","volume":"45","author":"Damas","year":"2000","journal-title":"Cardiovasc. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10753-011-9326-4","article-title":"Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction.","volume":"35","author":"De Gennaro","year":"2012","journal-title":"Inflammation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"R1972","DOI":"10.1152\/ajpregu.1997.273.6.R1972","article-title":"Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide.","volume":"273","author":"De Matteo","year":"1997","journal-title":"Am. J. Physiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"R1125","DOI":"10.1152\/ajpregu.1999.276.4.R1125","article-title":"Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep.","volume":"276","author":"de Matteo","year":"1999","journal-title":"Am. J. Physiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00392-007-0626-5","article-title":"Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock.","volume":"97","author":"Debrunner","year":"2008","journal-title":"Clin. Res. Cardiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study.","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail."},{"key":"B58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yjmcc.2013.03.020","article-title":"Components of the interleukin-33\/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.","volume":"60","author":"Demyanets","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1161\/ATVBAHA.111.231431","article-title":"Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques.","volume":"31","author":"Demyanets","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.112.125435","article-title":"Rehospitalization for heart failure: predict or prevent?","volume":"126","author":"Desai","year":"2012","journal-title":"Circulation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1161\/01.cir.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025009","article-title":"Akt regulates IL-10 mediated suppression of TNFalpha-induced cardiomyocyte apoptosis by upregulating Stat3 phosphorylation.","volume":"6","author":"Dhingra","year":"2011","journal-title":"PLoS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/cvr\/cvp040","article-title":"IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis.","volume":"82","author":"Dhingra","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein.","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cyto.2011.08.029","article-title":"Systemic inflammation and cell activation reflects morbidity in chronic heart failure.","volume":"56","author":"Dixon","year":"2011","journal-title":"Cytokine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijcard.2005.05.063","article-title":"Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention.","volume":"111","author":"Dominguez-Rodriguez","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsptsci.9b00099","article-title":"IL-33 in chronic respiratory disease: from preclinical to clinical studies.","volume":"3","author":"Donovan","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10741-019-09875-1","article-title":"Various aspects of inflammation in heart failure.","volume":"25","author":"Dutka","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/eurheartj\/ehm075","article-title":"Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.","volume":"28","author":"Dzav\u00edk","year":"2007","journal-title":"Eur. Heart J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cardfail.2020.10.002","article-title":"Soluble ST2 and diuretic efficiency in acute heart failure and concomitant renal dysfunction.","volume":"27","author":"Espriella","year":"2021","journal-title":"J. Card Fail."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure.","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2015.05.160","article-title":"Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.","volume":"196","author":"Farag","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1161\/hc5001.101749","article-title":"Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.","volume":"104","author":"Fichtlscherer","year":"2001","journal-title":"Circulation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.1631560","article-title":"Negative inotropic effects of cytokines on the heart mediated by nitric oxide.","volume":"257","author":"Finkel","year":"1992","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.15190\/d.2015.33","article-title":"Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts.","volume":"3","author":"Frangogiannis","year":"2015","journal-title":"Discoveries (Craiova)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation.","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis. Res. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease.","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/bcp.13855","article-title":"Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.","volume":"85","author":"Gan","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/0006-291x(85)91311-7","article-title":"Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo.","volume":"131","author":"Garcia","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/01.CCM.0000228919.33620.D9","article-title":"Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction.","volume":"34","author":"Geppert","year":"2006","journal-title":"Crit. Care Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","article-title":"IL-33 (Interleukin 33)\/sST2 axis in hypertension and heart failure.","volume":"72","author":"Ghali","year":"2018","journal-title":"Hypertension"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The xanthine oxidase inhibition for hyperuricemic Heart Failure patients (EXACT-HF) study.","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10741-013-9405-8","article-title":"Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.","volume":"19","author":"Glezeva","year":"2014","journal-title":"Heart Fail. Rev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2005.02.040","article-title":"The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.","volume":"151","author":"Gong","year":"2006","journal-title":"Am. Heart J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2012.06.528","article-title":"Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.","volume":"18","author":"Gotsman","year":"2012","journal-title":"J. Card Fail."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1084\/jem.190.12.1733","article-title":"C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.","volume":"190","author":"Griselli","year":"1999","journal-title":"J. Exp. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1067\/mhj.2001.112785","article-title":"Effect of metoprolol on cytokine levels in chronic heart failure\u2013a substudy in the metoprolol controlled-release randomised intervention trial in heart failure (MERIT-HF).","volume":"141","author":"Gullestad","year":"","journal-title":"Am. Heart J."},{"key":"B88","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/01.cir.103.2.220","article-title":"Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.","volume":"103","author":"Gullestad","year":"","journal-title":"Circulation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijcard.2012.09.092","article-title":"Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction.","volume":"168","author":"Gullestad","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1161\/CIRCULATIONAHA.105.564971","article-title":"Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study.","volume":"112","author":"Gullestad","year":"2005","journal-title":"Circulation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000338166","article-title":"Inflammatory cytokines in heart failure: mediators and markers.","volume":"122","author":"Gullestad","year":"2012","journal-title":"Cardiology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1096\/fj.201701173RR","article-title":"Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure.","volume":"32","author":"Halade","year":"2018","journal-title":"FASEB J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1161\/CIRCULATIONAHA.108.802918","article-title":"Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation.","volume":"119","author":"Hamid","year":"2009","journal-title":"Circulation"},{"key":"B94","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure.","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.","volume":"51","author":"Hare","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1172\/JCI29134","article-title":"provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways.","volume":"117","author":"Haudek","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B98","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ejhf.2082","article-title":"Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.","volume":"23","author":"Hazebroek","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1152\/japplphysiol.00419.2003","article-title":"iNOS activity is essential for endothelial stress gene expression protecting against oxidative damage.","volume":"95","author":"Hemmrich","year":"2003","journal-title":"J. Appl. Physiol. (1985)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","article-title":"Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial.","volume":"134","author":"Heydari","year":"2016","journal-title":"Circulation"},{"key":"B101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","article-title":"Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.","volume":"11","author":"Heymans","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1161\/01.CIR.0000075927.67673.F2","article-title":"Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.","volume":"107","author":"Hochman","year":"2003","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1161\/CIRCRESAHA.113.302024","article-title":"Is tumor necrosis factor-alpha friend or foe for chronic heart failure?","volume":"113","author":"Hori","year":"2013","journal-title":"Circ. Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jchf.2017.06.013","article-title":"Heart failure with mid-range (Borderline) ejection fraction: clinical implications and future directions.","volume":"5","author":"Hsu","year":"2017","journal-title":"JACC Heart Fail."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112359","article-title":"Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.","volume":"9","author":"Husebye","year":"2014","journal-title":"PLoS One"},{"key":"B106","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1586\/14779072.2015.1000307","article-title":"Predicting therapeutic response in patients with heart failure: the story of C-reactive protein.","volume":"13","author":"Huynh","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis.","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circ. Cardiovasc. Imag."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.","volume":"297","author":"Alexander","year":"2007","journal-title":"JAMA"},{"key":"B109","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cardfail.2008.06.450","article-title":"Activation of inducible NOS in peripheral vessels and outcomes in heart failure patients.","volume":"14","author":"Ishibashi","year":"2008","journal-title":"J. Card Fail."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/01.CIR.0000092184.43176.91","article-title":"Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue.","volume":"108","author":"Jabs","year":"2003","journal-title":"Circulation"},{"key":"B111","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B112","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/1567270010805030178","article-title":"C-reactive protein and atherosclerosis: An update.","volume":"5","author":"Jan","year":"2008","journal-title":"Vasc. Dis. Preven."},{"key":"B113","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2005.10.033","article-title":"Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.","volume":"115","author":"Jankowska","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"H1462","DOI":"10.1152\/ajpheart.00442.2009","article-title":"TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload.","volume":"297","author":"Jobe","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.44","article-title":"A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein transgenic mice and humans.","volume":"1","author":"Jones","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10441-8","article-title":"Resolution agonist 15-epi-Lipoxin A4 programs early activation of resolving phase in post-myocardial infarction healing.","volume":"7","author":"Kain","year":"2017","journal-title":"Sci. Rep."},{"key":"B117","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/clc.4960291103","article-title":"Nitric oxide synthase inhibitors in post-myocardial infarction cardiogenic shock\u2013an update.","volume":"29","author":"Kaluski","year":"2006","journal-title":"Clin. Cardiol."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-019-0101-5","article-title":"The role of interleukin-1 in general pathology.","volume":"39","author":"Kaneko","year":"2019","journal-title":"Inflamm. Regen."},{"key":"B119","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10741-008-9104-z","article-title":"Biology of TNFalpha and IL-10, and their imbalance in heart failure.","volume":"14","author":"Kaur","year":"2009","journal-title":"Heart Fail. Rev."},{"key":"B120","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure.","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc. Pathol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"H153","DOI":"10.1152\/ajpheart.01057.2009","article-title":"Resolvin E1 protects the rat heart against reperfusion injury.","volume":"299","author":"Keyes","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1681\/ASN.2003090757","article-title":"Maladaptive role of IL-6 in ischemic acute renal failure.","volume":"16","author":"Kielar","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214496","article-title":"Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease.","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-017-0609-2","article-title":"Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.","volume":"112","author":"Kingery","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1023\/a:1007726018470","article-title":"Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure.","volume":"12","author":"Kitakaze","year":"1998","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure.","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3899\/jrheum.131540","article-title":"Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.","volume":"41","author":"Kobayashi","year":"2014","journal-title":"J. Rheumatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1161\/01.ATV.0000248096.62495.73","article-title":"Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA\/KORA Augsburg case-cohort study, 1984-2002.","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock.","volume":"165","author":"Kohsaka","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2019.18598","article-title":"Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC randomized clinical trial.","volume":"322","author":"Kozhuharov","year":"2019","journal-title":"JAMA"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIRCRESAHA.108.188243","article-title":"IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR.","volume":"104","author":"Krishnamurthy","year":"2009","journal-title":"Circ. Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cardfail.2006.09.008","article-title":"Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.","volume":"13","author":"Krum","year":"2007","journal-title":"J. Card Fail."},{"key":"B136","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/s-0030-1250436","article-title":"Interleukin-33, a novel member of the IL-1\/IL-18 cytokine family, in cardiology and cardiac surgery.","volume":"58","author":"Kunes","year":"2010","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"B137","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0014-2999(90)94800-d","article-title":"Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells.","volume":"178","author":"Lanier-Smith","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.","volume":"323","author":"Levine","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"R590","DOI":"10.1152\/ajpregu.00207.2009","article-title":"Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells.","volume":"299","author":"Li","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"12746","DOI":"10.1073\/pnas.97.23.12746","article-title":"Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.","volume":"97","author":"Li","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B141","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.fjc.0000245242.57088.5b","article-title":"Potent potentiating diuretic effects of prednisone in congestive heart failure.","volume":"48","author":"Liu","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0828-282x(07)70840-1","article-title":"Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.","volume":"23","author":"Liu","year":"2007","journal-title":"Can. J. Cardiol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/FJC.0000000000000048","article-title":"Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure: COPE-ADHF study.","volume":"63","author":"Liu","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/clc.20812","article-title":"Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients.","volume":"33","author":"Lourenco","year":"2010","journal-title":"Clin. Cardiol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/s0735-1097(00)00912-8","article-title":"High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.","volume":"36","author":"Maeda","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability.","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1096\/fj.04-2426fje","article-title":"Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure.","volume":"18","author":"Mallat","year":"2004","journal-title":"FASEB J."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: the cytokine hypothesis revisited.","volume":"116","author":"Mann","year":"2015","journal-title":"Circ. Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"B150","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.amjcard.2010.09.011","article-title":"Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.","volume":"107","author":"Manzano-Fernandez","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2011.01.023","article-title":"The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?","volume":"30","author":"Massari","year":"2012","journal-title":"Am. J. Emerg. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/1744-9987.12796","article-title":"PentraSorb C-reactive protein: characterization of the selective c-reactive protein adsorber resin.","volume":"23","author":"Mattecka","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"B153","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-3083.1992.tb03087.x","article-title":"TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation.","volume":"36","author":"Mattila","year":"1992","journal-title":"Scand. J. Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.hfc.2017.08.005","article-title":"Soluble ST2 in heart failure.","volume":"14","author":"McCarthy","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150018","article-title":"A Study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus.","volume":"11","author":"McKie","year":"2016","journal-title":"PLoS One"},{"key":"B156","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00134-015-4041-5","article-title":"Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance.","volume":"42","author":"Mebazaa","year":"2016","journal-title":"Intensive Care Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrcardio.2015.134","article-title":"Pathophysiology and clinical evaluation of acute heart failure.","volume":"13","author":"Mentz","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cardfail.2006.11.013","article-title":"Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy.","volume":"13","author":"Michelucci","year":"2007","journal-title":"J. Card Fail."},{"key":"B159","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions.","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"H1813","DOI":"10.1152\/ajpheart.00036.2004","article-title":"In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure.","volume":"287","author":"Moe","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Phys."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.02.011","article-title":"Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.","volume":"161","author":"Moertl","year":"2011","journal-title":"Am. Heart J."},{"key":"B162","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23<3.0.CO;2-H","article-title":"Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum."},{"key":"B163","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cardfail.2009.06.439","article-title":"The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial).","volume":"15","author":"Moreira","year":"2009","journal-title":"J. Card Fail."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review.","volume":"75","author":"Murphy","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2019.02.022","article-title":"Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease.","volume":"493","author":"Ndrepepa","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"B166","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/cts.12859","article-title":"Early clinical experience with AZD4831, a novel myeloperoxidase inhibitor, developed for patients with heart failure with preserved ejection fraction.","volume":"14","author":"Nelander","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5603\/CJ.2013.0027","article-title":"Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.","volume":"20","author":"Nessler","year":"2013","journal-title":"Cardiol. J."},{"key":"B168","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2005.09.020","article-title":"Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.","volume":"152","author":"Ng","year":"2006","journal-title":"Am. Heart J."},{"key":"B169","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4330\/wjc.v8.i10.584","article-title":"Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure.","volume":"8","author":"Ng","year":"2016","journal-title":"World J. Cardiol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1574884714666190802125627","article-title":"A review of the role of statins in heart failure treatment.","volume":"15","author":"Niazi","year":"2020","journal-title":"Curr. Clin. Pharmacol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin.","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hft125","article-title":"Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA.","volume":"16","author":"Nymo","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"B173","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Mol. Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease.","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"key":"B175","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited.","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ. Res."},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/nature04672","article-title":"Targeting C-reactive protein for the treatment of cardiovascular disease.","volume":"440","author":"Pepys","year":"2006","journal-title":"Nature"},{"key":"B178","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cardfail.2021.01.006","article-title":"Interleukin-6 and outcomes in acute heart failure: An ASCEND-HF substudy.","volume":"27","author":"Perez","year":"2021","journal-title":"J. Card Fail."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/ATVBAHA.112.253427","article-title":"Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells.","volume":"33","author":"Pollheimer","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B182","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00392-011-0403-3","article-title":"Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock.","volume":"101","author":"Prondzinsky","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2459\/JCM.0000000000000974","article-title":"Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study.","volume":"21","author":"Pugliese","year":"2020","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology.","volume":"9","author":"Putko","year":"2014","journal-title":"PLoS One"},{"key":"B185","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4065\/mcp.2009.0494","article-title":"Chronic heart failure: contemporary diagnosis and management.","volume":"85","author":"Ramani","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"B186","first-page":"146","article-title":"Mechanism of cardioprotective action of TNF-alpha in the isolated rat heart.","volume":"7","author":"Rathi","year":"2002","journal-title":"Exp. Clin. Cardiol."},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3646","article-title":"Chronic heart failure in adults: summary of updated NICE guidance.","volume":"362","author":"Real","year":"2018","journal-title":"BMJ"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction.","volume":"373","author":"Redfield","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1373\/clinchem.2009.142257","article-title":"Use of myeloperoxidase for risk stratification in acute heart failure.","volume":"56","author":"Reichlin","year":"2010","journal-title":"Clin. Chem."},{"key":"B190","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s40635-019-0265-y1","article-title":"Inflammation and resolution of inflammation in human acute heart failure.","volume":"7","author":"Reina-Couto","year":"","journal-title":"Int. Care Med. Exp."},{"key":"B191","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/eci.13109","article-title":"Resolvins in human acute heart failure.","volume":"49","author":"Reina-Couto","year":"","journal-title":"Eur. J. Clin. Invest."},{"key":"B192","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/eci.12265","article-title":"Impaired resolution of inflammation in human chronic heart failure.","volume":"44","author":"Reina-Couto","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.2174\/1389450117666160101121135","article-title":"Resolving inflammation in heart failure: novel protective lipid mediators.","volume":"17","author":"Reina-Couto","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-020-00354-8","article-title":"Proinflammatory cytokines and endothelial cell activation in human acute heart failure versus septic shock.","volume":"8","author":"Reina-Couto","year":"2020","journal-title":"Int. Care Med. Exp."},{"key":"B195","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/01.cir.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"B196","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"B199","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"B200","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/1744-9987.12804","article-title":"Selective C-reactive protein-apheresis in patients.","volume":"23","author":"Ries","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4767105","article-title":"\u201cFirst in Man\u201d: case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction.","volume":"2018","author":"Ries","year":"2018","journal-title":"Case Rep. Cardiol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1042\/cs0920013","article-title":"Cardiovascular pharmacology of purines.","volume":"92","author":"Rongen","year":"1997","journal-title":"Clin. Sci. (Lond.)"},{"key":"B203","first-page":"213","article-title":"Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart.","volume":"10","author":"Saini","year":"2005","journal-title":"Exp. Clin. Cardiol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.","volume":"117","author":"Sanada","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B205","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2217\/bmm.14.24","article-title":"Clinical implications of different biomarkers in elderly patients with heart failure.","volume":"8","author":"Sanchez","year":"2014","journal-title":"Biomark Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/026765910101600110","article-title":"Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes.","volume":"16","author":"Sanders","year":"2001","journal-title":"Perfusion"},{"key":"B207","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.","volume":"47","author":"Scirica","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"287","DOI":"10.14744\/AnatolJCardiol.2019.32748","article-title":"Role of interleukins in heart failure with reduced ejection fraction.","volume":"22","author":"Segiet","year":"","journal-title":"Anatol. J. Cardiol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"305","DOI":"10.14744\/AnatolJCardiol.2019.64614","article-title":"The concentration of interleukin-33 in heart failure with reduced ejection fraction.","volume":"21","author":"Segiet","year":"","journal-title":"Anatol. J. Cardiol."},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1136\/heart.84.6.668","article-title":"Interleukin 18 in acute myocardial infarction.","volume":"84","author":"Seta","year":"2000","journal-title":"Heart"},{"key":"B211","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s1071-9164(96)80047-9","article-title":"Basic mechanisms in heart failure: the cytokine hypothesis.","volume":"2","author":"Seta","year":"1996","journal-title":"J Card Fail"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001409","article-title":"Effect of colchicine in reducing inflammatory biomarkers and cardiovascular risk in coronary artery disease: A meta-analysis of clinical trials.","author":"Sethuramalingam","year":"2021","journal-title":"Am. J. Ther."},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.630430","article-title":"C-reactive protein triggers cell death in ischemic cells.","volume":"12","author":"Sheriff","year":"2021","journal-title":"Front. Immunol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/17482941.2010.523705","article-title":"Cardiogenic shock: the role of inflammation.","volume":"12","author":"Shpektor","year":"2010","journal-title":"Acute Card Care"},{"key":"B215","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1161\/hc3401.093154","article-title":"Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.","volume":"104","author":"Sivasubramanian","year":"2001","journal-title":"Circulation"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/s0002-9149(02)02779-0","article-title":"Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.","volume":"90","author":"Sliwa","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/01.CIR.0000112568.48837.60","article-title":"Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.","volume":"109","author":"Sliwa","year":"2004","journal-title":"Circulation"},{"key":"B218","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"B219","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijcard.2020.01.039","article-title":"Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.","volume":"304","author":"Song","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/1874192401105010153","article-title":"Regulation of Inducible Nitric Oxide Synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure.","volume":"5","author":"Soskic","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"B221","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/978-981-13-8273-4_23","article-title":"Role of Oxidative Stress in the Pathophysiology of Arterial Hypertension and Heart Failure","author":"Sousa","year":"2019","journal-title":"Oxidative Stress in Heart Diseases"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2741\/456","article-title":"BNP and iNOS in decompensated chronic heart failure: a linear correlation.","volume":"4","author":"Speranza","year":"2012","journal-title":"Front Biosci (Elite Ed)."},{"key":"B223","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJMra022643","article-title":"Acute cardiac tamponade.","volume":"349","author":"Spodick","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11897-019-00451-0","article-title":"Heart failure with mid-range ejection fraction.","volume":"17","author":"Srivastava","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/01.RES.0000148635.73331.c5","article-title":"Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy.","volume":"95","author":"Stull","year":"2004","journal-title":"Circ. Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/01.cir.0000055318.09997.1f","article-title":"Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes.","volume":"107","author":"Suematsu","year":"2003","journal-title":"Circulation"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024579","article-title":"Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis.","volume":"100","author":"Sun","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","article-title":"Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.","volume":"115","author":"Sun","year":"2007","journal-title":"Circulation"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/353614","article-title":"Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.","volume":"2014","author":"Szalai","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B230","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40119-018-0104-3","article-title":"A review of interleukin-1 in heart disease: where do we stand today?","volume":"7","author":"Szekely","year":"2018","journal-title":"Cardiol. Ther."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.115.016379","article-title":"Xanthine oxidase inhibitors in heart failure: where do we go from here?","volume":"131","author":"Tamariz","year":"2015","journal-title":"Circulation"},{"key":"B232","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1751-7133.2011.00200.x","article-title":"Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis.","volume":"17","author":"Tamariz","year":"2011","journal-title":"Congest. Heart Fail."},{"key":"B233","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pharmthera.2013.12.013","article-title":"Targeting NOS as a therapeutic approach for heart failure.","volume":"142","author":"Tang","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B234","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure.","volume":"98","author":"Tang","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jacc.2007.02.053","article-title":"Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.","volume":"49","author":"Tang","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","author":"Tavazzi","year":"","journal-title":"Lancet"},{"key":"B237","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","author":"Tavazzi","year":"","journal-title":"Lancet"},{"key":"B238","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.","volume":"351","author":"Taylor","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B239","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijcard.2003.08.002","article-title":"Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy.","volume":"94","author":"Tentolouris","year":"2004","journal-title":"Int. J. Cardiol."},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/372432","article-title":"Targeting C-Reactive protein in inflammatory disease by preventing conformational changes.","volume":"2015","author":"Thiele","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure.","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail."},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.695952","article-title":"Heart failure syndrome with preserved ejection fraction is a metabolic cluster of non-resolving inflammation in obesity.","volume":"8","author":"Tourki","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B243","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1096\/fj.202000495RR","article-title":"Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity.","volume":"34","author":"Tourki","year":"2020","journal-title":"FASEB J."},{"key":"B244","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.","volume":"18","author":"Tschope","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s0735-1097(97)00494-4","article-title":"Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.","volume":"31","author":"Tsutamoto","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IJICMR.S64894","article-title":"TNF-\u03b1 in the cardiovascular system: from physiology to therapy.","volume":"7","author":"Urschel","year":"2015","journal-title":"Int. J. Interferon Cytokine Media. Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: A scientific statement from the american heart association.","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"B248","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation - cause or consequence of heart failure or both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/cpt.1637","article-title":"The quest for antiinflammatory and immunomodulatory strategies in heart failure.","volume":"106","author":"Van Linthout","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B250","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure: A randomized, double-blinded, placebo-controlled pilot study.","volume":"67","author":"Van Tassell","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction.","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"B255","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/01.cir.0000057810.48709.f6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"key":"B257","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.105.542340","article-title":"Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction.","volume":"112","author":"Vasilyev","year":"2005","journal-title":"Circulation"},{"key":"B258","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1006\/jmcc.1998.0686","article-title":"Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure.","volume":"30","author":"Vejlstrup","year":"1998","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/CIRCULATIONAHA.112.112185","article-title":"Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB.","volume":"126","author":"Verma","year":"2012","journal-title":"Circulation"},{"key":"B260","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s003950050007","article-title":"Leukemia inhibitory factor and interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes.","volume":"95","author":"Villegas","year":"2000","journal-title":"Basic Res. Cardiol."},{"key":"B261","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000492602","article-title":"Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1.","volume":"8","author":"Virzi","year":"2018","journal-title":"Cardiorenal. Med."},{"key":"B262","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/SHK.0b013e318160f215","article-title":"Interleukin 18 in the heart.","volume":"30","author":"Wang","year":"2008","journal-title":"Shock"},{"key":"B263","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/phar.2401","article-title":"Colchicine for secondary cardiovascular prevention: A systematic review.","volume":"40","author":"Webb","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B264","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1042\/CS20050317","article-title":"Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support.","volume":"110","author":"White","year":"2006","journal-title":"Clin. Sci. (Lond)"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247972","article-title":"A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function.","volume":"16","author":"Wlodek","year":"2021","journal-title":"PLoS One"},{"key":"B266","first-page":"8247","article-title":"Expression and significance of inflammatory reactions mediated by the IL-33\/ST2 signaling pathway in the serum of heart failure patients.","volume":"13","author":"Xiang","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.140","article-title":"The emerging role of Toll-like receptor 4 in myocardial inflammation.","volume":"7","author":"Yang","year":"2016","journal-title":"Cell. Death Dis."},{"key":"B268","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/ehf2.13350","article-title":"High density lipoprotein cholesterol \/ C reactive protein ratio in heart failure with preserved ejection fraction.","volume":"8","author":"Yano","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0002-9440(10)64051-5","article-title":"Generation of C-reactive protein and complement components in atherosclerotic plaques.","volume":"158","author":"Yasojima","year":"2001","journal-title":"Am. J. Pathol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","article-title":"Systemic inflammation in heart failure\u2013the whys and wherefores.","volume":"11","author":"Yndestad","year":"2006","journal-title":"Heart Fail. Rev."},{"key":"B271","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/03009742.2017.1418424","article-title":"Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms.","volume":"47","author":"Yokoe","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"B272","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1172\/JCI116834","article-title":"Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart.","volume":"92","author":"Yokoyama","year":"1993","journal-title":"J. Clin. Invest."},{"key":"B273","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"B274","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/a:1006896832582","article-title":"TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function.","volume":"177","author":"Zell","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"B275","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1536\/ihj.49.587","article-title":"Prednisone adding to usual care treatment for refractory decompensated congestive heart failure.","volume":"49","author":"Zhang","year":"2008","journal-title":"Int. Heart J."},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-120","article-title":"Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress.","volume":"10","author":"Zhang","year":"2012","journal-title":"J. Transl. Med."},{"key":"B277","first-page":"103","article-title":"Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.","volume":"9","author":"Zhang","year":"2004","journal-title":"Exp. Clin. Cardiol."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.RES.0000264081.78659.45","article-title":"Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.","volume":"100","author":"Zhang","year":"2007","journal-title":"Circ. Res."},{"key":"B279","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/HYPERTENSIONAHA.111.173328","article-title":"Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage.","volume":"59","author":"Zhang","year":"2012","journal-title":"Hypertension"},{"key":"B280","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00395-009-0026-2","article-title":"Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?","volume":"104","author":"Zimmermann","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"B281","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1161\/CIRCULATIONAHA.105.605519","article-title":"Nitroso-redox interactions in the cardiovascular system.","volume":"114","author":"Zimmet","year":"2006","journal-title":"Circulation"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.746494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:08:21Z","timestamp":1634144901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.746494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":281,"alternative-id":["10.3389\/fphys.2021.746494"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.746494","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"article-number":"746494"}}